Other languages MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
2.25 ^USD	+7.14%		-18.18%	-71.01%

Apr. 09	Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	MT
Apr. 09	Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	Apr. 09
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	Apr. 09
Top Premarket Gainers	Apr. 09
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement	Mar. 05
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split	Feb. 13
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	Dec. 06
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	23-10-19
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023	23-10-04
Insider Buy: Mymd Pharmaceuticals	23-08-24
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
MyMD Pharmaceuticals Says Its Investigational New Drug Application for Rheumatoid Arthritis Treatment Gets FDA Acceptance	23-08-14
FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis	23-08-14
MyMD Pharmaceuticals' MYMD-1 Study Shows Positive Results for Age-Related inflammation Drug; Shares Rise	23-07-31
Mymd Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral Tnf-A Inhibitor Mymd-1® in Sarcopenia/Age-Related Frailty	23-07-31
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
MyMD Pharmaceuticals Says Phase 2 Trial of Treatment for Sarcopenia, Frailty Shows No Safety Issues	23-04-12
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
MyMD Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Other languages

Filters